Emerging therapeutic approaches in renal cell carcinoma

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer. J Clin 2013;63(1):11-30
   Google Scholar
• Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353(23):2477-90
   PubMed Web of Science ®Google Scholar
• Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13(3):688-96
   PubMed Web of Science ®Google Scholar
• Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 2008;113(2):293-301
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Bukowski R, et al. Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer 2013;108(12):2470-7
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev 2010;36(5):416-24
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584-90
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind Phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer 2013;49(6):1287-96
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369(8):722-31
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised Phase III trial. Lancet Oncol 2013;14(6):552-62
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378(9807):1931-9
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27(20):3312-18
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010;116(18):4256-65
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 2012;30(12):1371-7
   PubMed Web of Science ®Google Scholar
• Atkinson BJ, Kalra S, Wang X, et al. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol 2014;191(3):611-18
   PubMed Web of Science ®Google Scholar
• Najjar YG, Mittal K, Elson P, et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer 2014;50(6):1084-9
   PubMed Web of Science ®Google Scholar
• Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24(1):25-35
   PubMed Web of Science ®Google Scholar
• Sunitinib scheduling in metastatic renal cell carcinoma (mRCC). Available from: https://clinicaltrials.gov/ct2/show/NCT02060370
   Google Scholar
• Rini BI, Melichar B, Fishman MN, et al. Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. Ann Oncol 2015;26(7):1372-7
   PubMed Web of Science ®Google Scholar
• Rini BI, Melichar BTY. Overall survival analysis from a randomized phase II study of axitinib with or without dose titration for first-line metastatic renal cell carcinoma. J Clin Oncol 2015;33:suppl; abstr 4545
   PubMed Web of Science ®Google Scholar
• Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(9):1432-9
   PubMed Web of Science ®Google Scholar
• Rini BI, Garcia JA, Cooney MM, et al. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res 2009;15(19):6277-83
   PubMed Web of Science ®Google Scholar
• Sosman J, Atkins MFK, McDermott D, et al. Updated results of phase I trial of sorafenib and bevacizumab in patient with metastatic renal cell cancer. J Clin Oncol 2008;26(Suppl): abstract 5011
   Google Scholar
• McDermott D, Pins MMJ, Flaherty K, et al. The BeST Trial (ECOG 2804): a randomized phase II study of VEGF, RAF kinase, and MTOR combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma. J Clin Oncol 2013;31(Suppl 6; abstract 345
   Web of Science ®Google Scholar
• Rini BI, Bellmunt J, Clancy J, et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 2014;32(8):752-9
   PubMed Web of Science ®Google Scholar
• Ravaud A, Anak OBC. Randomized phase II study of first-line everolimus (EVE) þ bevacizumab (BEV) versus interferonalfa-2a(IFN) þ BEV inpatients (pts) with metastatic renal cell carcinoma (mRCC): RECORD-2. Ann Oncol 2012;23:7830; Meeting abstracts
   Google Scholar
• Motzer R, Glen HHT, Michaelson D, et al. Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN + EVE in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2015;33:suppl; abstr 4506
   PubMed Web of Science ®Google Scholar
• Eskens FA, de Jonge MJ, Bhargava P, et al. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. Clin Cancer Res 2011;17(22):7156-63
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 2013;31(30):3791-9
   PubMed Web of Science ®Google Scholar
• Vaishampayan U. Cabozantinib as a novel therapy for renal cell carcinoma. Curr Oncol Rep 2013;15(2):76-82
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Pal SK, McDermott DF, et al. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol 2014;25(8):1603-8
   PubMed Web of Science ®Google Scholar
• Cabozantinib-s-malate or sunitinib malate in treating patients with previously untreated locally advanced or metastatic kidney cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01835158
   Google Scholar
• A study of cabozantinib (XL184) vs everolimus in subjects with metastatic renal cell carcinoma (METEOR). Available from: https://clinicaltrials.gov/ct2/show/NCT01865747
   Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192(7):1027-34
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012;24(2):207-12
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252-64
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8(8):793-800
   PubMed Web of Science ®Google Scholar
• Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8(6):467-77
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009;114(8):1537-44
   PubMed Web of Science ®Google Scholar
• Drake CG, Sznol M, et al. Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up. Clin Oncol 2013;suppl; abstr 4514
   Google Scholar
• Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol 2015;33(13):1430-7
   PubMed Web of Science ®Google Scholar
• Plimack ER, Rini BI. Updated survival results from a randomized, dose-ranging Phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2015;33:suppl; abstr 4553
   PubMed Web of Science ®Google Scholar
• Study of nivolumab (BMS-936558) vs everolimus in pre-treated advanced or metastatic clear-cell renal cell carcinoma (CheckMate 025). Available from: https://clinicaltrials.gov/ct2/show/NCT01668784
   Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366(26):2455-65
   PubMed Web of Science ®Google Scholar
• Cho DC, Sznol M. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013;suppl; abstr 4505
   Google Scholar
• Amin A, Infante JR, Ernstoff MS, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2014;32:5s-suppl; abstr 5010
   PubMed Web of Science ®Google Scholar
• Nivolumab (BMS-936558; MDX-1106) in combination with sunitinib, pazopanib, or ipilimumab in subjects with metastatic renal cell carcinoma (RCC) (CheckMate 016). Available from: https://clinicaltrials.gov/ct2/show/NCT01472081
   Google Scholar
• McDermott DF, Sosman JA. Immune correlates and long term follow up of a phase Ia study of MPDL3280A, an engineered PD-L1 antibody, in patients with metastatic renal cell carcinoma (mRCC). Ann Oncol Proceedings of the European Society of Medical Oncology Meeting 2014, Madrid, 2014, Abstract 809O
   Google Scholar
• A phase 2 study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as monotherapy or in combination with avastin (bevacizumab) compared to sunitinib in patients with untreated advanced renal cell carcinoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01984242
   Google Scholar
• A Study of MPDL3280A (Anti-programmed death ligand 1 [PD-L1] Antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma. Available from: https://clinicaltrials.gov/ct2/show/NCT02420821
   Google Scholar
• Chambers CA, Kuhns MS, Egen JG, et al. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001;19:565-94
   PubMed Web of Science ®Google Scholar
• Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007;30(8):825-30
   PubMed Web of Science ®Google Scholar
• Hammers HJ, Infante JR. Expanded cohort results from CheckMate 016: A Phase 1 study of nivolumab in combination with ipilimumab in the metastatic renal cell carcinoma (mRCC). J Clinc Oncol 2015;33:suppl; abstr 4516
   Google Scholar
• Nivolumab combined with ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma (CheckMate 214). Available from: https://clinicaltrials.gov/ct2/show/NCT02231749
   Google Scholar
• Choueiri TK, Escudier BJ. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. J Clin Oncol 2014;32:5s-suppl; abstr 5012
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier BJ. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes. J Clin Oncol 2015;33:suppl; abstr 4500
   PubMed Web of Science ®Google Scholar
• Xin H, Zhang C, Herrmann A, et al. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009;69(6):2506-13
   PubMed Web of Science ®Google Scholar
• Sharpe K, Stewart GD, Mackay A, et al. The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. Clin Cancer Res 2013;19(24):6924-34
   PubMed Web of Science ®Google Scholar
• A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies (MDX1106-03). Available from: https://clinicaltrials.gov/ct2/show/NCT00730639
   Google Scholar
• Phase I Biomarker Study (BMS-936558). Available from: https://clinicaltrials.gov/ct2/show/NCT01358721
   Google Scholar
• BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC). Available from: https://clinicaltrials.gov/ct2/show/NCT01354431
   Google Scholar
• A Phase 1 study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in patients with locally advanced or metastatic solid tumors. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01375842
   Google Scholar